Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
3.000
-0.180 (-5.66%)
Nov 21, 2024, 11:07 AM EST - Market open
Marker Therapeutics Employees
Marker Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 59 or -88.06% compared to the previous year.
Employees
8
Change (1Y)
-59
Growth (1Y)
-88.06%
Revenue / Employee
$674,481
Profits / Employee
-$1,212,095
Market Cap
26.77M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Nortech Systems | 775 |
Pluri | 118 |
IRIDEX | 111 |
Tonix Pharmaceuticals Holding | 103 |
ImmuCell | 79 |
Passage Bio | 58 |
OneMedNet | 20 |
NeurAxis | 19 |
MRKR News
- 6 days ago - Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma - GlobeNewsWire
- 6 months ago - Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 8 months ago - Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies - GlobeNewsWire
- 8 months ago - Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results - GlobeNewsWire
- 8 months ago - Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 10 months ago - Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 - GlobeNewsWire